9 results
8-K
EX-99.2
GRTS
Gritstone Bio Inc
4 Jan 22
Other Events
5:21pm
Demographics Subject ID Gender Age Weeks post 2nd Vaxzevria dose 0001 M 63 30 0002 F 64 30 0003 F 63 22 0004 M 63 22 0005 M 69 25 0007 F 63 24 0008 M 81 25 … -grade fever and injections site reactions, consistent with potent vaccine Demographics and Tumor Types n=26 Age: mean (range) 60 (38-77) Gender: Female
8-K
EX-99.1
GRTS
Gritstone Bio Inc
13 Jan 20
Other Events
6:15am
Indicative of an Inflammatory Response Demographics n = 6 Age (mean, range) 66 (50-76) Gender (Female/Male) 2/4 # of doses ChAdV 6 SAM 20 Nivolumab (IV … in Combination with Nivolumab and Ipilimumab Well Tolerated To Date Demographics n = 3 Age (mean, range) 71 (64-83) Gender (Female/Male) 1/2 # of doses ChAdV 3
8-K
EX-99.1
GRTS
Gritstone Bio Inc
13 Jul 20
Other Events
4:07pm
Treated Metastatic Patients GRANITE SLATE (n=10) (n=19) Age (mean, range) 59 (38-76) 58 (33-83) Gender (Female/Male) 4/6 12/7 # of doses ChAdV 11 19 … ) Gender (Female/Male) 4/6 12/7 # of doses ChAdV 11 19 SAM 44 39 Nivolumab (IV) 61 58 Ipilimumab (SC) 14 47 Tumor Types NSCLC 1 6 Microsatellite stable
- Prev
- 1
- Next